Five-Plus-Five Equals A Focus On Execution At Lilly In 2023

Approvals Near For Four New Drugs, One New Indication

 
• By Mandy Jackson

Executives told Scrip the company is ready to move five programs into Phase III and launch five products this year, including an obesity indication for Mounjaro, but one drug has since received a CRL.

Office building at Lilly's Indianapolis HQ
Lilly's donanemab setback still could result in a win with positive Phase III data in Q2 • Source: Shutterstock

More from New Products

More from Scrip